SEC Comment Letter for VYNE Therapeutics Inc. (VYNE) (CIK 0001566044) (VYNE) — May 10, 2021
VYNE Therapeutics Inc. (VYNE) (CIK 0001566044)
Date: May 10, 2021 · CIK: 0001566044 · Accession: 0000000000-21-005942
AI Filing Summary & Sentiment
File numbers found in text: 333-255841
Letter
United States securities and exchange commission logo May 10, 2021 Mutya Harsch, Esq. Chief Legal Officer and General Counsel VYNE Therapeutics Inc. 520 U.S. Highway 22, Suite 204 Bridgewater, New Jersey 08807 Re:VYNE Therapeutics Inc. Registration Statement on Form S-3 Filed May 6, 2021 File No. 333-255841 Dear Ms. Harsch: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at (202) 551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Andrea L. Nicolas, Esq.
Show Raw Text
United States securities and exchange commission logo
May 10, 2021
Mutya Harsch, Esq.
Chief Legal Officer and General Counsel
VYNE Therapeutics Inc.
520 U.S. Highway 22, Suite 204
Bridgewater, New Jersey 08807
Re:VYNE Therapeutics Inc.
Registration Statement on Form S-3
Filed May 6, 2021
File No. 333-255841
Dear Ms. Harsch:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at (202) 551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Andrea L. Nicolas, Esq.